Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription 18.03.2024 2 AIDS 1 Arch Virol 1 BMC Pediatr 2 Clin Infect Dis 1 Infect Immun 1 J Gen Virol 8 J Infect Dis 1 JAMA 3 Lancet 2 N Engl J Med 1 Nat Immunol 3 PLoS One 20 Vaccine 1 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. FRESSE A, Massy N, Fournier D, Pinel S, et al
   Adverse drug reaction profile of third-generation smallpox vaccines used in France during the 2022 monkeypox epidemic.
   AIDS. 2024;38:768-771.
   PubMed         Abstract available
   
   
2. KEBEDE S, Brazier E, Freeman AM, Muwonge TR, et al
   PrEP Availability Among Health Facilities Participating in the Global IeDEA Consortium.
   AIDS. 2023 Dec 22. doi: 10.1097/QAD.0000000000003824.
   PubMed         Abstract available
   
   

   
   Arch Virol

3. LATIFI T, Kachooei A, Jalilvand S, Zafarian S, et al
   Correlates of immune protection against human rotaviruses: natural infection and vaccination.
   Arch Virol. 2024;169:72.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

4. AKANPAABADAI EA, Adiak AA, Nukpezah RN, Adokiya MN, et al
   Population-based cross-sectional study of factors influencing full vaccination status of children aged 12- 23 months in a rural district of the Upper East Region, Ghana.
   BMC Pediatr. 2024;24:168.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

5. PINEDA-PENA AC, Jiang Q, Petit C, Korejwo-Peyramond J, et al
   Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free, Compared With Two Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized Controlled Phase III Trial.
   Clin Infect Dis. 2024 Mar 13:ciae137. doi: 10.1093.
   PubMed         Abstract available
   
   
6. SHRESTHA NK, Burke PC, Nowacki AS, Gordon SM, et al
   Effectiveness of the 2023-2024 Formulation of the Coronavirus Disease 2019 mRNA Vaccine.
   Clin Infect Dis. 2024 Mar 11:ciae132. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Infect Immun

7. VANCE DJ, Basir S, Piazza CL, Willsey GG, et al
   Single-domain antibodies reveal unique borrelicidal epitopes on the Lyme disease vaccine antigen, outer surface protein A (OspA).
   Infect Immun. 2024 Mar 12:e0008424. doi: 10.1128/iai.00084.
   PubMed         Abstract available
   
   

   
   J Gen Virol

8. BAI W, Zhu Q, Wang J, Jiang L, et al
   Licorice extract inhibits porcine epidemic diarrhea virus in vitro and in vivo.
   J Gen Virol. 2024;105.
   PubMed         Abstract available
   
   

   
   J Infect Dis

9. GIULIANO AR, Palefsky JM, Goldstone SE, Dubin B, et al
   High Risk of New HPV Infection Acquisition Among Unvaccinated Young Men.
   J Infect Dis. 2023 Nov 28:jiad485. doi: 10.1093.
   PubMed         Abstract available
   
   
10. ROSSLER A, Knabl L, Netzl A, Bante D, et al
    Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus Disease 2019 Vaccine Booster.
    J Infect Dis. 2024;229:644-647.
    PubMed         Abstract available
    
    
11. SEPULVEDA-PACHON IT, Dunne EM, Hanquet G, Baay M, et al
    Effect of pneumococcal conjugate vaccines on viral respiratory infections: a systematic literature review.
    J Infect Dis. 2024 Mar 11:jiae125. doi: 10.1093.
    PubMed         Abstract available
    
    
12. MUNK C, Reinholdt K, Kjaer AK, Hemmingsen CH, et al
    Prevalence of Human Papillomavirus (HPV) and HPV Type Distribution in Penile Samples in Young Men in Denmark: Results 10 Years After Implementation of a Girls-Only HPV Vaccination Program.
    J Infect Dis. 2024 Mar 12:jiae068. doi: 10.1093.
    PubMed         Abstract available
    
    
13. FIERRO C, Brune D, Shaw M, Schwartz H, et al
    Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1, Randomized, Clinical Trial.
    J Infect Dis. 2024 Mar 13:jiae114. doi: 10.1093.
    PubMed         Abstract available
    
    
14. GRUNER E, Grossegesse M, Stern D, Ober V, et al
    Mpox-specific immune responses elicited by vaccination or infection in people living with HIV.
    J Infect Dis. 2024 Mar 13:jiae138. doi: 10.1093.
    PubMed         Abstract available
    
    
15. VAN TOL S, Fletcher P, Feldmann F, Mukesh RK, et al
    A bivalent Adenovirus-Vectored Vaccine induces a robust humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus.
    J Infect Dis. 2024 Mar 15:jiae056. doi: 10.1093.
    PubMed         Abstract available
    
    
16. PRASAD AN, Geisbert TW
    A glass-half-full perspective on negative data in Ebolavirus vaccine studies.
    J Infect Dis. 2024 Mar 15:jiae109. doi: 10.1093.
    PubMed        
    
    

    
    JAMA

17. HARRIS E
    New Prevention Guidance for Antibiotic-Resistant Meningococcal Cases.
    JAMA. 2024 Feb 21. doi: 10.1001/jama.2024.0731.
    PubMed        
    
    

    
    Lancet

18. SHAWE-TAYLOR M, Greenwood D, Hobbs A, Dowgier G, et al
    Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
    Lancet. 2024 Mar 11:S0140-6736(24)00316-7. doi: 10.1016/S0140-6736(24)00316.
    PubMed        
    
    
19. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    PubMed        
    
    
20. PARHIZ H, Atochina-Vasserman EN, Weissman D
    mRNA-based therapeutics: looking beyond COVID-19 vaccines.
    Lancet. 2024 Mar 7:S0140-6736(23)02444-3. doi: 10.1016/S0140-6736(23)02444.
    PubMed         Abstract available
    
    

    
    N Engl J Med

21. RASMUSSEN SA, Jamieson DJ
    Maternal RSV Vaccine - Weighing Benefits and Risks.
    N Engl J Med. 2024;390:1050-1051.
    PubMed        
    
    
22. DIEUSSAERT I, Hyung Kim J, Luik S, Seidl C, et al
    RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes.
    N Engl J Med. 2024;390:1009-1021.
    PubMed         Abstract available
    
    

    
    Nat Immunol

23. FUMAGALLI V, Rava M, Marotta D, Di Lucia P, et al
    Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination.
    Nat Immunol. 2024 Mar 14. doi: 10.1038/s41590-024-01787.
    PubMed         Abstract available
    
    

    
    PLoS One

24. PANG Y, Robbs C, Wang J
    A longitudinal study of the COVID-19 pandemic impact on mental health in ophthalmic personnel and students.
    PLoS One. 2024;19:e0300144.
    PubMed         Abstract available
    
    
25. SUWANBAMRUNG C, Srinam B, Promkool P, Suwannakarn W, et al
    Uptake of COVID-19 vaccine among high-risk urban populations in Southern Thailand using the COM-B model.
    PLoS One. 2024;19:e0300509.
    PubMed         Abstract available
    
    
26. ARUMAE K, Realo A, Ausmees L, Allik J, et al
    Self- and informant-reported personality traits and vaccination against COVID-19.
    PLoS One. 2024;19:e0287413.
    PubMed         Abstract available
    
    

    
    Vaccine

27. EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al
    Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study.
    Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
28. MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al
    The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial.
    Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
29. 
    Expression of Concern: "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages 108-116].
    Vaccine. 2024;42:1851.
    PubMed        
    
    
30. 
    Expression of Concern: "Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses" [Vaccine Volume 38, Issue 4, 22 January 2020, Pages 830-839].
    Vaccine. 2024;42:1850.
    PubMed        
    
    
31. MALDONADO I, Rodriguez Nino N, Valencia CF, Ortiz D, et al
    Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia.
    Vaccine. 2024 Mar 7:S0264-410X(24)00263-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
32. GILBERT PB, Fong Y, Hejazi NS, Kenny A, et al
    Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial.
    Vaccine. 2024 Mar 7:S0264-410X(24)00247-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
33. SIREK G, Ulysse S, Jacques Toussaint M, Nosamiefan C, et al
    A community-engaged approach to translate a Vaccine Hesitancy Scale into Haitian Creole.
    Vaccine. 2024 Mar 7:S0264-410X(24)00257-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
34. DE WAELE A, Hendrickx G, Valckx S, Dominguez A, et al
    The Vaccine Training Barometer: Assessing healthcare providers' confidence to answer vaccine-related questions and their training needs.
    Vaccine. 2024 Mar 7:S0264-410X(24)00254-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
35. BROUSSEAU N, Angers-Goulet ME, Bastien R, Ye L, et al
    Vaccination during pregnancy and modulation of IgG response to pertussis vaccines in infants: The impact of different vaccine formulations.
    Vaccine. 2024 Mar 8:S0264-410X(24)00300-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
36. LUISI M, Geana MV, Pei J
    Pandemic antecedents - Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination.
    Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
37. SU YW, Qiu YZ, Wang YH, Xu Y, et al
    Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
    Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
38. HARRELL JE, Roy CJ, Gunn JS, McLachlan JB, et al
    Current vaccine strategies and novel approaches to combatting Francisella infection.
    Vaccine. 2024 Mar 8:S0264-410X(24)00264-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
39. MORO PL, Carlock G, Fifadara N, Habenicht T, et al
    Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
40. SENPUKU K, Kataoka-Nakamura C, Kunishima Y, Hirai T, et al
    An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice.
    Vaccine. 2024 Mar 11:S0264-410X(24)00303-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
41. SHIJIA YAN A, Jay Sehgal N
    Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S.
    Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
42. MERDRIGNAC L, Ait El Belghiti F, Pandolfi E, Acosta L, et al
    Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 201
    Vaccine. 2024 Mar 11:S0264-410X(24)00272-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
43. RUSS S, Myers C, Licherdell E, Bowden A, et al
    Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
    Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
44. SHERMAN SM, Allerton-Price C, Lingley-Heath N, Lai J, et al
    UK healthcare professionals' attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration.
    Vaccine. 2024 Mar 12:S0264-410X(24)00274-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
45. CHEUNG DH, Chen S, Fang Y, Sun F, et al
    Influences of mpox disease perceptions, sources and contents of information exposure on mpox vaccine uptake among gay, bisexual, and other men who have sex with men in Hong Kong, China.
    Vaccine. 2024 Mar 12:S0264-410X(24)00259-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
46. SAKAUE T, Sugawara T, Mukasa K, Nohara M, et al
    Varicella outbreak at nursery school under routine immunization in Japan in 2017 and 2018 and vaccine effectiveness.
    Vaccine. 2024 Mar 12:S0264-410X(24)00250-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    

    
    Virology

47. ZHENG X, Yang R, Zhao Y, Zhang Y, et al
    Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity.
    Virology. 2024;594:110050.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.